( ntire immune system thesetherapeutic ...)Orchestra Therapeutics Announces New Phase II Clinical Data on,NeuroVax Demonstrating Marked Expansion of Regulatory T Cell,Populations in Patients With Multiple Sclerosis,Health

This news release contains forward-looking statements. Forward-looking statements are often signaled by forms of words such as should, could, will, might, plan, projection, forecast, expect, guidance, potential and developing. Actual results could vary materially from those expected due to a variety of risk factors, including whether the Company will continue as a going concern and successfully raise proceeds from financing activities sufficient to fund operations and clinical trials of NeuroVax(TM), Remune(R) or IR103, the uncertainty of successful completion of any such clinical trials, the fact that the Company has not succeeded in commercializing any drug, the risk that NeuroVax(TM), Remune(R) or IR103 might not prove to be effective as a therapeutic vaccine, whether future trials will be conducted and whether the results of such trials will coincide with the results of NeuroVax(TM), Remune(R) or IR103 in preclinical trials and/or earlier clinical trials and the unresolved status of the Company's HIV program. A more extensive set of risks is set forth in Orchestra Therapeutics' SEC filings including, but not limited to, its Annual Report on Form 10-K for the year ended December 31, 2006, and its subsequent Quarterly Report filed on Form 10-Q. The Company undertakes no obligation to update the results of these forward-looking statements to reflect events or circumstances after today or to reflect the occurrence of unanticipated events.

NeuroVax(TM) is a trademark of Orchestra Therapeutics, Inc. Remune(R) is a registered trademark of Orchestra Therapeutics, Inc.

    MEDIA CONTACT:

    Rachel Kessler

    Chamberlain Communications Group

    (212) 389-9155

    


    INVESTOR CONTACT:

    Robert Giordano

    ROI Associates

    (212) 495-0201

'"/>




Page: 1 2 3 4 5 
Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement
of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule
Therapeutic Clinical Trial Results Presented at the 34th Annual
Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of
Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into
Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to
Sustained Reductions in Blood Glucose Levels for 6 Months
Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for
Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical
Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II
Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on
Visceral Fat and Insulin Resistance at American Diabetes
Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of
Efaproxyn in Women With Brain Metastases Originating From Breast
Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and
Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase
2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care